Совершенствование адъювантной внутрипузырной химиотерапии немышечно-инвазивного рака мочевого пузыря
Диссертация
Наибольший удельный вес среди всех впервые выявленных случаев рака приходится на так называемый немышечно-инвазивный рак, который соответствует по классификации TNM (2002г.) заболеванию в стадии Та, Т1 и CIS: опухолям, распространяющиймся в пределах слизистой и подслизистого слоя мочевого пузыря без поражения регионарных лимфатических узлов и отдаленных метастазов. По данным отечественных… Читать ещё >
Список литературы
- Parkin D.M., Bray F., Felay J., et al. Estimated the world cancer burden // Globocan 2000. Int. J. Cancer. 2001. — Vol. 94 — P. 153 — 156.
- Лопаткин H.A. Даренков С. П. Чернышов A.E. // Радикальное лечения инвазивного рака мочевого пузыря. Урология. — 2003. № 4. — С. 3−8.
- М.И. Давыдов, Аксель Е. М. Злокачественные новообразования в России и странах СНГ в 2005 // Медицина.: Вестник Российского Онкологического научного центра им. Н. Н. Блохина. РАМН. 2007. — Вып. 18 (2). — С. 55.
- Ries L.A., Eissner М.Р., Kosaiy at al. SEER Cancer Statistics Review, 19 752 000 / Bethesda: National Cancer Institute, 2003.
- Flesher N.E., Herr H.W., Steart A.K., et al. The National cancer data Base report on Bladder Carcinoma. The American college of surgeons Commission on Cancer and The American Cancer Society // Cancer. 1996. — Vol. 78. — P. 1505.
- Messing E.M., Catalona W. Urotelial tumors of the urinary tract // In Campbell’s Urology. 7th ed. Edited by P.C. Walsh et al. Philadelphia: W.B. Saunders. 1998. — Vol. 77. — P.2327 — 2408.
- Heney N.M., Ahmed S., Flanagan M.J. et al. Superficial bladder cancer. Progression and recurrence // J. Urol. 1983. — Vol. 130. — P.1083.
- Sobin D.H., Wittekind Ch. In: TNM classification of malignant tumours / 6th edn. New York: Wiley-Liss, 2002. P. 199−202
- Waters W.B. Invasive bladder cancer — where do we go from here? // Editorial. J.Urol. 1996.-Vol. 155.-P. 1940−1911.
- Kirkali Z., Chan Т., Manocharan et al. Bladder cancer: epimemiology, staging and grading, and diagnosis // Urology. 2005. — Vol. 66. — P. 4 -34.
- Ro J.Y., Starerkel G.A., Ayala A.G. Cytologic and histologic features of superficial bladder cancer // Urol. Clin. North Am. 1992. — Vol. 19 (3). — P. 435 -453.
- Аль Шукри C.X., Ткачук B.H. Опухоли мочеполовых органов // СПб.: Питер, 2000. -30 с.
- Гущин Б. JI. Клинико-морфологические сопоставления при раке мочевого пузыря, дис.. канд. мед. наук. -М., 1995. 174 с.
- Grignon P.J. Neoplasm (of) urinary bladder / Ed. by David G. et al. // Urologic syrgical pathology. Eble. 1997. -P. 215 — 305.
- Переверзев A.C., Петров С. Б. Опухоли мочевого пузыря // Харьков: Факт, 2002.-372 с.
- Kantor A.F., Hartge P., Hoover R.N., et al. Epidemiological characteristics of squamosus cellcarcinoma of the bladder // Cancer Res. 1988. — Vol. 48. — P. 3853.
- Lynch C.F. and Cohen M.B. Urinaiy system cancer. 1995. — Vol. 75. — P. 316.
- Mostofi F.K., Davis C.J., Sesterhenn I.A. Histological typing of urinary bladder tumours. In: World HealthOrganization international histologic classification of tumours. — 2nd edn. Heidelberg: Springer-Verlag, 1999.
- Коган М.И., Перепечай В. А. Радикальная цистэктомия. Современный взгляд. В кн.: Актуальные вопросы лечения онкоурологических заболеваний: Материалы 4-й Всероссийской науч.- практич. конф. с участием стран СНГ // М.2001. 113−114.
- Soloway M.S. The management of superficial bladder cancer. In: Javadpour N.ed. Principles of Management Urologic Cancer 2nd. ed. Baltimore MP: Williams and Wilkins. 1983. — P. 446 — 447.
- Amling C.L., Tracher J.B., Fraizer H.A., et al. Radical cystectomy for stages Та, Tis and TI transitional cell carcinoma of the bladder // J. Urol. 1994. Vol. 151 (l).-P. 31−36.
- Shelfo S.W., Brady J.D. and Soloway M.S. Transurethral resection of the bladder cancer / Atlas Urol. Clin. N.A. 1997. — Vol. 5. — P. 1.
- Аль Шукри C.X. Всероссийское общество урологов. Пленум: Тезисы докладов. Кемерово, 1995.-С. 188−189.
- Руководство по урологии. Т. З. Под ред. Н. А. Лопаткина. — М., 1998.
- Русаков И.Г. Современные подходы к лечению онкоурологических заболеваний. Симпозиум: Тезисы докладов. — М., 1998. С. 8−11.
- Лоран О.Б. Рак мочевого пузыря: Материалы конф. Ростов н/Д, 1998. -С. 58−60.
- Мс Kierman J.M., Kaplan S.A., Sarantosa R.P. Ibid. 1996. — Vol. 48, №. — P. 199−210.
- Traxer O., Pasqui F., Gatteno B. Technique and complications of transurethral surgery for bladder tumors // BJU Int. 2004. — Vol. 94. — P. 492 — 496.
- Soloway M. Optimal transurethral resection of bladder tumors. Optimal therapy for patients with high risk superficial bladder canccr controversy and consensus // Oxford: Medcine Publishing. — 1997. — P. 31 — 35.
- Русаков И.Г., Быстров A.A. Хирургическое лечение, химио и иммунотерапия больных поверхностным раком мочевого пузыря // Практическая онкология. 2003. -Т.4, № 4. — С. 214 — 224.
- Лопаткин Н.А., Мартов А. Г., Гущин Б. Л. с соавт. Лечение рака мочевого пузыря // Урол. и нефрол. 1998. — № 5. — С. 9 — 12.
- Мартов А.Г., Камалов А. А. Гущин Б.Л. // Актуальные вопросы лечения онкоурологических заболеваний. Обнинск, 1997. — С. 49 — 50.
- Чепуров А.К., Нейменова А. А. // Урол. и нефрол. 1996. — 32. — С. 21 -23.
- Dalesio О., Shulman C.C., Sylvester R., et al. Prognostic factors in the superficial bladder tumors. A study of the European Organization for Research and Treatment Cancer: Genito-Urinary Tract Cooperative Group // J. Urol. 1983. -Vol.129.-P. 730−733.
- Dutta S.C., Smith J.A. Jr., Shappell S.B., Coffey C.S., Chang S.S. and Cookson M.S. Clinical understaging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy // J. Urol. 2001. — Vol. 166. — P. 490.
- Schwaibold H.E., Sivalingam S., May F. and Hartung R. The value of second transurethral resection for TI bladder cancer // BJU Int. 2006. — Vol. 97. — P. 1199.
- Brauers A., Buettner R. and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy of ten too early? // J. Urol.-2001.-Vol. 165.-P. 808.
- Shwaibold Hartwing, Treiber Uwe, Kubler Hubert et all. Significant of 2 tranuretral resection for TI bladder cancer // Eur. Urol. 2000. — Vol. 37(Suppl. 2) 1−175.-P. 100.
- Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors // J. Urol. 1999. — Vol. 162. — P. 74.
- Dalbagni G., Herr H.W. and Reuter V.E. Impact of a second transurethral resection on thestaging of TI bladder cancer // Urology. 2002. — Vol. 60. — P. 822.
- Fitzpatrick J.M., West A.B., Butler M.A. et al. J. Urol. (Baltimore). 1986. -Vol. 135.-P. 920−922.
- Lamm D.L. Urol. Clin. N. Am. 1992. — Vol. 19. — P. 499 — 508.
- Близнюк В.М. Обоснование методов хирургического лечения эпителиальных опухолей мочевого пузыря: Автореф. дис.. д-ра мед. наук.-Свердловск, 1964. — С. 23.
- Карпенко B.C., Романенко A.M., Гойхберг М. И. Эпителиальные опухоли мочевого пузыря. Киев: Здоровье, 1986. — С. 173.
- Баженов И.В. Медицинская и трудовая реабилитация больных раком мочевого пузыря: Дис.. канд. мед. наук. Свердловск, 1990. — С. 56 — 66.
- Лопаткин Н.А., Мартов А. Г., Даренков С. П. Оперативное лечение опухолей мочевого пузыря // Урол. и нефрол. 1999. — Т. 1. — С. 26 — 31.
- Flohr, P., Hefty, R., Paiss, Т. and Hautmann, R.: The ileal neobladder-updater experience with 306 patients // World J. Urol. 1996. — Vol. 14. — P. 22.
- Hautmann, R.E., Miller, K., Steiner, U. and Wenderoth, U. The ileal neobladder: 6 years of experience with more than 200 patients // J. Urol. 1993. -Vol. 150.-P. 40.
- Bianco F.J. Jr., Justa D., Grignon D.J., et al. Management of clinical TI bladder transitional cell carcinoma by radical cystectomy // Urol. Oncol. 2004. -Vol. 22.-P. 290.
- Stein J.P., Lieskovsky G., Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients // J Clin. Oncol. — 2001.-Vol. 19.-P. 666.
- Herr H.W. and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? // J. Urol. 2001. — Vol. 166. -P. 1296.
- Cookson M.S., Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome // J. Urol. 1997. — Vol. 158. — P. 62 — 67.
- Шипилов В.И. Рак мочевого пузыря. М.: Медицина, 1983. — 192 с.
- Dalesio О., Shulman С.С., Sylvester R., et al. Prognostic factors in superficial bladder tumors: a study of the EORTC: Genito — Urinary Tract Cancer Cooperative Group // J. Urol. 1983. — Vol. 129. — P. 730 — 733.
- Witjes J.A. Prognosis and treatment of superficial bladder cancer. — Nijmegen, Drukkerij Quickprint, 1993.
- Schellhammer P.F. What is the available evidence to support immediate adjuvant intravesical chemotherapy after transurethral resection of superficial transitional cell carcinoma of the bladder? // Urol. Oncol. 1998. — Vol. 4. — P. 73 -79.
- Devesa S.S., Blot W.J., Stone B.J., et al. Recent cancer trends in the United States // J. Natl. Cancer Inst. 1995. — Vol. 87. — P. 175−182.
- Abel P.D.: Prognostic indices in transitional cell carcinoma of the bladder // Br. J. Urol. 1988. — Vol. 62. — P. 103−109.
- Soloway MS, Sofer M, Vaidya A. Contemporary management of stage Tl transitional cell carcinoma of the bladder // J Urol. 2002. — Vol. 167(4). — P. 1573 — 1583.
- Chan D., Di Song, Wientjes M.G. et al. Effect of Dimethyl Sulfoxide on Bladder Tissue Penetration of Intravesical Paclitaxel // Clin. Cancer Research. -2003. Vol. 9. — P. 363 — 369.
- Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M., al. Factors affecting recurrence and progression in superficial bladder tumours // Eur. J. Cancer.-1995.-Vol. 31 A.-P. 1840.
- Solsona E., Iborra I., Dumon R., Rubio-Briones J., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer // J. Urol. 2000. — Vol. 164. — P. 685.
- Lamm DL et al. Semin urology. 1992. — Vol. 10. — P. 39 — 44.
- Oosterlink W., van der Meijden, Sylvester R., et al. Guidelines on TaTl (non-muscle invasive) bladder cancer. European Association of Urology Guidelines Arnhem (The Netherlands): European Association of Urology. — 2006. — P. 1 — 17.
- Messing E.M. and Catalona W. Urothelial tumors of the urinary tract. In: Campbell’s Urology, 7th ed. Edited by P.C. Walsh, A.B. Retik, et al. Philadelphia: W. B. Saunders. 1998. — Vol. 77. — P. 2327 — 2408.
- Hudson M.A. and Herr H.W.: Carcinoma in situ of the bladder // J. Urol. — 1995.-Vol. 153.-P. 564.
- Lamm D.L. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder // Oncology. 1995. — Vol. 9. — P. 947.
- Connolly J.G. Chemotherapy of superficial bladder cancer. Carcinoma of the bladder. Connolly J.G., ed. Raven, New York, 1981. — P. 165 — 175.
- Фигурин K.M. Химиотерапия и иммунотерапия рака мочевого пузыря. Дисс. д-ра мед. наук.- М. 1993.
- Матвеев Б.П., Фигурин К. М., Карякин О. Б. Рак мочевого пузыря. — М.: Вердана, 2001.-С. 243.
- Алексеев Б.Я. Внутрипузырная иммунотерапия поверхностного рака мочевого пузыря: Автореф. дис. канд. мед. наук. -М., 1998.
- Матвеев Б.П. Рак мочевого пузыря, под ред. Б. П. Матвеева. — М.: Вердана, 2003. С. 197−406.
- Cookson M.S. and Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette Guerin therapy // J. Urol. — 1992. — Vol. 148.-P. 797.
- Bohle A., Gerdes J., Ulmer A.J., et al. Effect of local Bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall // J. Urol. 1990. — Vol. 144. — P. 53 — 58.
- Rijtema M., Mosig D., Drukker A., et al. The effects of dimethyl sulfoxide on renal function of the newborn rabbit // Biol. Neonate. 1999. — Vol. 76. — P. 355 -361.
- Kaasinen E., Rintala E., Hellstrom P., et al. Finn Bladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma // Eur. Urol. — 2002. Vol. 42. -P. 167- 174.
- Solsona E., Iborra I., Ricos J.V., et al. Effectiveness of a single immediate mitomycin С instillation in patients with low risk superficial bladder cancer: short and long-term followup // J. Urol. 1999. — Vol. 161. — P. 1120 — 1123.
- Doll D.C. et al. // J. Clin. Oncol. 1985. — Vol. 3. — P. 2776 — 2786.
- Trasher J.B., Crawford E.D. Complications of intravesical chemotherapy // Urol. Clin. North Am. 1992. — Vol. 19. — P. 529 — 539.
- Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder // N. Engl. J. Med. 1991. — Vol. 325 (17).-P. 1205- 1209.
- Burnard K.G., Boyd P.J., Mayo M.E., et al. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma // Br. J. Urol. 1976. — Vol. 49. — P. 55 — 59.
- Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder // J. Clin. Oncol. 2002. — Vol. 20. — P. 3193 — 3198.
- Hall M.C., Chang S.S., Dalbagni G. et al. Bladder cancer clinical guidelines update panel. Guideline for the management of nonmuscle invasive bladder cancer: (stages Та, TI and Tis). The American Urological Association. — 2007. — P. 193.
- Urdaneta G., Solsona E., Palou J. Intravesical chemotherapy and BCG for the treatment of bladder cancer: Evidence and option // Eur. Urol. Suppl. 2008. -Vol. 7 (7). — P. 542 — 547.
- Tolly D.A., Parmar M.C., Grigor K.M., et al. The effect of intravesical mitomycin С on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up // J. Urol. 1996. — Vol. 155. — P. 1233 -1238.
- Solsona E., Iborra I., Ricos J.V., et al. Effectiveness of a single immediate mitomycin С instillation in patients with low risk superficial bladder cancer: short and long-term followup // J. Urol. 1999. — Vol. 161. — P. 1120.
- Kaasinen E., Rintala E., Hellstrom P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimes for frequently recurring superficial bladder carcinoma // Eur. Urol. 2002. — Vol. 42. — P. 167 — 174.
- Hendricksen K., Kiemeney L.A., Caris C., et al. Three shedules of adjuvant intravesical doxorubicin in patients with non-muscle invasive bladder cancer: a comparative study // Eur. Urol. Suppl. 2007. — Vol. 6. — P. 60.
- Oosterlinck W., Lobel В., Jakse G., et al. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer // Eur. Urol. 2002. — Vol. 24. — P. 105 — 112.
- Hendricksen K., Witjes J.A. Treatment of intermediate-risk non-muscle bladder cancer (NMIBC) // Eur. Urol. 2007. — Vol. 6 (14). — P. 801.
- Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials // Urology. 2006. — Vol. 67. — P. 1216.
- Huncharek M., Geschwind J.F., Witherspoon В., et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials // J. Clin. Epidemiol. 2000. — Vol. 53. -P. 676.
- Shelley M.D., Court J., Kynaston H., et al. Intravesical bacillus Calmette-Guerin in Та Tl bladder cancer // Cohrane database of systematic rewiews. 2000. -CD 1 986.
- Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG on recurrence of superficial transitional cell carcinoma of the bladder: a metaanalytic reevaluation // Am. J. Clin. Oncol. 2003. — Vol. 26. — P. 402 — 407.
- Moutzouris G., Lykourinas M., Malovrovas D., et al. Prospective, randomized, comparative study of high dose intravesical epirubicin, versus BCG for prophylaxis in intermediate risk superficial bladder tumors // Eur. Urol. Suppl. -2007.-Vol. 6.-P. 171.
- Oosterlinck W., Witjes J.A., Sylvester RJ. Diagnostic and prognostic factors in non-muscle invasive bladder cancer and their influence on treatment and outcomes // Eur. Urol. Suppl. 2008. — Vol. 7(7). — P. 520.
- Jakes G., Algaba F., Malstrom P.-U. et al. A second look TUR in Tl transitional cell carcinoma: why? /I Eur. Urol. 2004. — Vol. 45. — P. 539 — 546.
- Nieder A.M., Brausi M., Lamm D., et al. Management of stage Tl tumors of the bladder: International Consensus Panel // Urology. 2005. — Vol. 66. — P. 108 — 125.
- Bohle A., Jocham D. and Bock P.R. Intravesical bacillus calmette-guerin versus mitomycin С for superficial bladder cancer: a formal meta-analysis ofcomparative studies on recurrence and toxicity // J. Urol. 2003. — Vol. — 169. — P. 90.
- Lundholm C., Norlen B.J., Ekman P., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin С and bacillus Calmette-Guerin in patients with superficial bladder carcinoma // J. Urol. 1996. -Vol. 156.-P. 372.
- Witjes J.A. Managemant of BCG failure in superficial bladder cancer: a review // Eur. Urol. 2006. — Vol. 49. — P. 790 — 797.
- Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients // J. Clin. Oncol. -2001. Vol. 19. — P. 666 — 675.
- Kiemeney L.A., Witjes J.A., Verbeek A.L. et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group // Br. J. Cancer. 1993. — Vol. 67. — P. 806 — 812.
- Shrier B.P., Hollander M.P., van Rhijn B.W. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumors and implications of therapy // Eur. Urol. 2004. — Vol. 45. — P. 292 — 296.
- Catalona W.J., Hudson M.A., Gillen D.P., et al. Risks and benefits of repeated courses of intravesical bacillus Calmettte-Guerin therapy for superficial bladder cancer // J. Urol. 1987. — Vol. 137. — P. 220.
- Баженов И. В. Зырянов A.B., Борзунов И. В. с соавт. Повторная местная иммунотерапия в лечение неинвазивного рака мочевого пузыря. Материалы III конгресса Российского общества онкоурологов, 2−3 октября 2008 г. — 2008.- С. 84 85.
- Wientjes, М. G., Badalament, R. A., and Au, J. L-S. Use of pharmacologict
- Dalton, J., Wientjes M.G., Badalament R.A., et al. Pharmacokinetics of intravesical mitomycin С in superficial bladder cancer patients // Cancer Res. — 1991.-Vol. 51.-P. 5144−5152.
- Colombo R., Da Pozzo L.F., Lev A., et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors // J. Urol. 1998. — Vol. 159 (3). — P. 783 -787.
- Colombo R., Brausi M., Da Pozzo L., et al. Thermo-chemotherapy and electromotive drug administration of mitomycin С in superficial bladder cancer eradication, a pilot study on marker lesion // Eur. Urol. 2001. — Vol. 39. — P. 95 — 100.
- Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin С versus passive transport mitomycin С for high risk superficial bladder cancer: a prospective randomized study // J. Urol. 2003. — Vol. 170. — P. 777−782.
- А.И. Ролевич, О. Г. Суконко, C.A. Красный, А.Г., с соавт. Внутрипузырный электрофорез доксорубицина при поверхностном раке мочевого пузыря. Результаты проспективного рандомизированного исследования // Онкоурология. 2005. — № 2. — С. 34 — 40.
- Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high risk superficial bladder cancer: randomized controlled trial // Lancet Oncol. 2006. — Vol. 7. — P. 43 — 51.
- Riedle C.R., Knoll M., Plas E. Electromotive drug administration and hydrodistension for the treatment of interstitial cystitis // J. Endourol. 1988. -Vol. 12(3).-P. 269−272.
- Lu Z., Yeh Т.К., Tsai M., et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy // Clin. Cancer Res. 2004. — Vol. 10. — P. 7677−7684.
- Eroglu M., Irmak S., Acar A., et al. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer // Int. J. Pharmacol. 2002. — Vol. 235. — P. 51 — 59.
- Le Visage C., Rioux-Leclercq N., Haller M., et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer//J Urol. 2004. — Vol. 171.-P. 1324−1329.
- Schoenfeld R.H., Belville W.D., Jacob S.W., et al. The effect of dimethylsulfoxide on the uptake of cisplatin from the urinary bladder of the dog: a pilot study // J. Am. Osteopath. Assoc. 1983. — Vol. 82. — P. 570 — 573.
- Hashimoto H., Tokunaka S., Sasaki et al. Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder // Urol. Res. 1992. -Vol. 20.-P. 233−236.
- Wood D.C., and Wood J. Pharmacologic and biochemical considerations of dimethylsulfoxide. Ann. N. Y. Acad. Sci. — 1975. — Vol. 243. — P. 7 — 18.
- Jacob S.W. and Herschler R. Pharmacology of DMSO // Cryobiology. 1986. -Vol. 23.-P. 14−27.